Mid-Year Healthcare Investments & Exits Report

The mid-year SVB /Leerink investments and exits reports is now out. This group does a nice job tapping their own data combined with a significant subscription with PitchBook to generate a report worth reviewing. “Despite a tough macroeconomic market with dwindling IPOs and downward spiraling public market valuations, Q1 investment was surprisingly robust totaling $23… Continue reading Mid-Year Healthcare Investments & Exits Report

Response to the WSJ

The following is a quick note we sent to the Wall Street Journal in response to publishing an incorrect narrative on the state of venture investing and capital raising by startups. The title of the post is: “Why Its Hard to Get Startup Funding Now – And What To Do About It.” Their post was… Continue reading Response to the WSJ

A List Advisors

A-List Startup Advisors “Don’t expect your investors or advisors to have the answers to all of your big questions. They might know the basic stuff off the top of their head, or know who to introduce you to, but on the big decisive stuff tell them instead that it’s their job to be a sparring… Continue reading A List Advisors

Closing Time for Capital Market Investors

It’s official folks, the dance is over. Turn off the music and the last one out gets the lights. You don’t have to go home but you can’t stay here. The Fed (the Federal Open Market Committee) busted into the school gymnasium and stole the punchbowl by raising rates and ending Quantitative Easing. The impact… Continue reading Closing Time for Capital Market Investors

TearSolutions: Naturally Treating Dry Eye (225)

TearSolutions’ lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our… Continue reading TearSolutions: Naturally Treating Dry Eye (225)

Five Tips for Turning Rejections Into a Successful Raise

Every founder is bound to be turned down by multiple people, but that doesn’t mean their ideas aren’t great. DocSend, now owned by DropBox, is one of our favorite fundraising tools. They recently shared a post by Max Fleitmann, Founding Partner, Wizard Venture. Max lays out some comfort food for everyone going through the agony… Continue reading Five Tips for Turning Rejections Into a Successful Raise

Sage Medical: Bringing Intelligence to Medical Coding & Billing (224)

With Sage’s AI Driven Medical Coding, Billing and Dictation, practitioners are eliminating the costly overhead of a medical coder while increasing productivity by 20%. The easy-to-use mobile app processes in real-time, eliminates coding & billing errors while increasing revenue by $250k+ ARR. – Apple– Spotify

From Ukraine to Uganda – Project Cure Delivers Critical Medical Equipment and Supplies (223)

Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise of Project Cure. Project C.U.R.E. was founded in 1987 to address the staggering shortage of medical resources around the world. Project C.U.R.E. has become the world’s largest distributor of donated medical… Continue reading From Ukraine to Uganda – Project Cure Delivers Critical Medical Equipment and Supplies (223)

Fast Yes Fast No – Tools for Effectively Raising Capital

The kiss of death for any startup raising capital is hearing “maybe.” As much as it may seem painful, presume “maybe” is “no” and move on. You are better off aggregating more interested parties than spending time trying to move the fence-sitters off the fence. But, let’s step back and deconstruct the process. The critical… Continue reading Fast Yes Fast No – Tools for Effectively Raising Capital

DelNova: Addressing complications from Botox (217)

DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects… Continue reading DelNova: Addressing complications from Botox (217)